123 related articles for article (PubMed ID: 37988414)
1. Artificial intelligence-aided detection for prostate cancer with multimodal routine health check-up data: an Asian multi-center study.
Song Z; Zhang W; Jiang Q; Deng L; Du L; Mou W; Lai Y; Zhang W; Yang Y; Lim J; Liu K; Park JY; Ng CF; Ong TA; Wei Q; Li L; Wei X; Chen M; Cao Z; Wang F; Chen R
Int J Surg; 2023 Dec; 109(12):3848-3860. PubMed ID: 37988414
[TBL] [Abstract][Full Text] [Related]
2. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.
Hansen J; Auprich M; Ahyai SA; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Fisch M; Abbou CC; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Pummer K; Graefen M; Haese A; Walz J; Briganti A; Shariat SF; Chun FK
Eur Urol; 2013 Feb; 63(2):201-9. PubMed ID: 22854248
[TBL] [Abstract][Full Text] [Related]
3. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
[TBL] [Abstract][Full Text] [Related]
4. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
[TBL] [Abstract][Full Text] [Related]
6. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
[TBL] [Abstract][Full Text] [Related]
7. An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study.
Pantanowitz L; Quiroga-Garza GM; Bien L; Heled R; Laifenfeld D; Linhart C; Sandbank J; Albrecht Shach A; Shalev V; Vecsler M; Michelow P; Hazelhurst S; Dhir R
Lancet Digit Health; 2020 Aug; 2(8):e407-e416. PubMed ID: 33328045
[TBL] [Abstract][Full Text] [Related]
8. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
McKiernan J; Noerholm M; Tadigotla V; Kumar S; Torkler P; Sant G; Alter J; Donovan MJ; Skog J
BMC Urol; 2020 Sep; 20(1):138. PubMed ID: 32873277
[TBL] [Abstract][Full Text] [Related]
9. Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population.
Chiu PK; Roobol MJ; Nieboer D; Teoh JY; Yuen SK; Hou SM; Yiu MK; Ng CF
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):99-104. PubMed ID: 27897172
[TBL] [Abstract][Full Text] [Related]
10. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
11. Improving prostate biopsy decision making in Mexican patients: Still a major public health concern.
Amaya-Fragoso E; García-Pérez CM
Urol Oncol; 2021 Dec; 39(12):831.e11-831.e18. PubMed ID: 34193378
[TBL] [Abstract][Full Text] [Related]
12. Urine spermine and multivariable Spermine Risk Score predict high-grade prostate cancer.
Chiu PK; Fung YH; Teoh JY; Chan CH; Lo KL; Li KM; Tse RT; Leung CH; Wong YP; Roobol MJ; Wong KL; Ng CF
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):542-548. PubMed ID: 33408349
[TBL] [Abstract][Full Text] [Related]
13. Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
Park JY; Yoon S; Park MS; Choi H; Bae JH; Moon DG; Hong SK; Lee SE; Park C; Byun SS
PLoS One; 2017; 12(1):e0168917. PubMed ID: 28046017
[TBL] [Abstract][Full Text] [Related]
14. Artificial intelligence for the diagnosis of clinically significant prostate cancer based on multimodal data: a multicenter study.
Zhang H; Ji J; Liu Z; Lu H; Qian C; Wei C; Chen S; Lu W; Wang C; Xu H; Xu Y; Chen X; He X; Wang Z; Zhao X; Cheng W; Chen X; Pang G; Yu G; Gu Y; Jiang K; Xu B; Chen J; Xu B; Wei X; Chen M; Chen R; Cheng J; Wang F
BMC Med; 2023 Jul; 21(1):270. PubMed ID: 37488510
[TBL] [Abstract][Full Text] [Related]
15. The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study.
Liang Y; Ketchum NS; Louden C; Jimenez-Rios MA; Thompson IM; Camarena-Reynoso HR
Urol Int; 2012; 89(1):9-16. PubMed ID: 22626812
[TBL] [Abstract][Full Text] [Related]
16. Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population.
Wu YS; Fu XJ; Na R; Ye DW; Qi J; Lin XL; Liu F; Gong J; Zhang N; Jiang GL; Jiang HW; Ding Q; Xu J; Sun YH
Asian J Androl; 2019; 21(6):592-597. PubMed ID: 30924451
[TBL] [Abstract][Full Text] [Related]
17. Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
Deniffel D; Healy GM; Dong X; Ghai S; Salinas-Miranda E; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Perlis N; Haider MA
Radiology; 2021 Aug; 300(2):369-379. PubMed ID: 34032510
[TBL] [Abstract][Full Text] [Related]
18. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
19. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
20. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
